TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20663642

Group type: EXPERIMENTAL
Intervention: Posterior-stabilized (PS) TKA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) TKA
Number of subjects: 40
Study: 19952576

Group type: EXPERIMENTAL
Intervention: Unstable resistance training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stable resistance training
Number of subjects: 40
Study: 17449194

Group type: EXPERIMENTAL
Intervention: Low pretreatment EBV DNA (<1,500 copies/mL) and undetectable posttreatment EBV DNA (pre-L/post-U)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: High pretreatment EBV DNA (>=1,500 copies/mL) and undetectable posttreatment EBV DNA (pre-H/post-U)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Low or high pretreatment EBV DNA and detectable posttreatment EBV DNA (pre-L or H/post-D)
Number of subjects: 152
Study: 15197209

Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin
Number of subjects: 152

Group type: COMPARATOR
Intervention: Cyclophosphamide/cisplatin
Number of subjects: 152
Study: 11704447

Group type: EXPERIMENTAL
Intervention: Group 1: anesthetic induction with halothane, maintenance with isoflurane, nitrous oxide (N2O), and oxygen (O2), LMA removed when child awakened
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Group 2: anesthetic induction and maintenance as in Group 1, LMA removed while child anesthetized with age adjusted 2 minimum alveolar concentration (MAC) end‐tidal concentration of isoflurane
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Group 3: anesthetic induction and maintenance with sevoflurane, N2O, and O2, LMA removed when child awakened
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Group 4: anesthetic induction and maintenance as in Group 3, but LMA removed while child anesthetized with age‐adjusted 2 MAC end‐tidal concentration of sevoflurane
Number of subjects: 123

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 123
Study: 9715923

Group type: EXPERIMENTAL
Intervention: Unvarying long-term home-based exercise program
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 124
Study: 8063980

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CB)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Brief psychodynamic therapy (PD)
Number of subjects: 66
Study: 2736876

Group type: EXPERIMENTAL
Intervention: Heart rate response to deep breathing
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cross-correlation test
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Valsalva ratio
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Abnormal results in deep breathing
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Abnormal results in cross-correlation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Abnormal Valsalva ratio
Number of subjects: 23
Study: 1256483

Group type: EXPERIMENTAL
Intervention: Automated Multiphasic Health Testing
Number of subjects: 574

Group type: COMPARATOR
Intervention: Non-screened subjects
Number of subjects: 574
Study: 31782814

Group type: EXPERIMENTAL
Intervention: Budesonide (BD; 256 μg) plus Montelukast (MNT; 10 mg) for 2 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Budesonide (BD; 256 μg) for 2 weeks
Number of subjects: 46
Study: 30291868

Group type: EXPERIMENTAL
Intervention: MRE (MR elastography) estimated liver stiffness after 24 weeks of treatment with selonsertib
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MRI-PDFF (MR imaging estimated proton density fat fraction) after 24 weeks of treatment with selonsertib
Number of subjects: 54
Study: 28274214

Group type: EXPERIMENTAL
Intervention: Integrated child malnutrition prevention and treatment intervention package
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1000
Study: 25052217

Group type: EXPERIMENTAL
Intervention: Intravenous dimenhydrinate (100 mg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intravenous piracetam (2000 mg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 94
Study: 22750079

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 21700922

Group type: EXPERIMENTAL
Intervention: Prism adaptation (PA) therapy - repetitive pointing with prism glasses inducing rightward optical shift, twice daily, 5 days per week, for 2 weeks.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group - similar pointing training with neutral glasses.
Number of subjects: 38
Study: 18208636

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10 microg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (20 microg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10 and 20 microg/d)
Number of subjects: 0
Study: 15936046

Group type: EXPERIMENTAL
Intervention: Salient local stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small sized compound letters (where global shape was more salient)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salient irrelevant stimulus
Number of subjects: 0
Study: 12972982

Group type: EXPERIMENTAL
Intervention: 0.4 mg TRH
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 10966008

Group type: EXPERIMENTAL
Intervention: Abciximab-treated patients undergoing emergency CABG
Number of subjects: 12
Study: 9332904

Group type: EXPERIMENTAL
Intervention: Saccadic eye movements in schizophrenic patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Saccadic eye movements in fast-group patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Saccadic eye movements in patients with hallucination and delusion symptoms
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Saccadic eye movements in ordinary group patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Saccadic eye movements in fast group patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saccadic eye movements in controls
Number of subjects: 46
Study: 8252959

Group type: EXPERIMENTAL
Intervention: Rotation (R) group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonrotation (NR) group
Number of subjects: 40
Study: 3958225

Group type: EXPERIMENTAL
Intervention: Sublingual administration of triazolam 0.5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral administration of triazolam 0.5 mg
Number of subjects: 8
Study: 31302579

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® (5 μg or 2.5 μg)
Number of subjects: 5165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5165

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat®
Number of subjects: 5165
Study: 29562145

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1096

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1096
Study: 26670129

Group type: EXPERIMENTAL
Intervention: Elastic compression stocking (ECS) therapy for 2 years
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Elastic compression stocking (ECS) therapy with ability to put on independently
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ECS therapy
Number of subjects: 300
Study: 25012415

Group type: EXPERIMENTAL
Intervention: CBASP (Cognitive Behavioral Analysis System of Psychotherapy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CBASP
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cingulum
Number of subjects: 10
Study: 22395144

Group type: EXPERIMENTAL
Intervention: Omission of the bladder flap (n=127)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Creation of the bladder flap (n=131)
Number of subjects: 258
Study: 20113765

Group type: EXPERIMENTAL
Intervention: Once-weekly supervised pulmonary rehabilitation (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Twice-weekly supervised pulmonary rehabilitation (n=15)
Number of subjects: 30
Study: 17108670

Group type: EXPERIMENTAL
Intervention: Nicotine mouth spray (1 mg/actuation)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nicotine gum (2 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nicotine inhaler
Number of subjects: 100
Study: 15968231

Group type: EXPERIMENTAL
Intervention: Short-term family therapy (10 sessions over 6 months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Long-term family therapy (20 sessions over 12 months)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Long-term treatment for subjects with severe eating-related obsessive-compulsive features or from nonintact families
Number of subjects: 86
Study: 12716087

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum at 15 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum at 10 mm Hg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recipients' kidneys
Number of subjects: 0
Study: 10232739

Group type: EXPERIMENTAL
Intervention: IL-2-treated autologous bone marrow (BM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IL-2-treated peripheral stem cells (PSCs)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IL-2 treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 by continuous i.v. infusion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Maintenance IL-2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IL-2-treated patients with lymphoma
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IL-2-treated patients with acute leukemia
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IL-2-treated patients with myeloid leukemia
Number of subjects: 36
Study: 8550853

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX) 1,000 mg/m2 intravenously over 24 h
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lower-dose methotrexate (LDMTX) 30 mg/m2 by mouth every 6 h x 6
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HDMTX
Number of subjects: 150

Group type: COMPARATOR
Intervention: LDMTX
Number of subjects: 150
Study: 1987712

Group type: EXPERIMENTAL
Intervention: Psychological stress monitoring and intervention (GHQ greater than or equal to 5)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Routine medical care after discharge (Control)
Number of subjects: 461
Study: 6122111

Group type: EXPERIMENTAL
Intervention: Oral diazoxide
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (diuretic + beta‐adrenoceptor blocker + hydralazine + prazosin)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (conventional stepped-care regimen)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Overall treatment outcomes
Number of subjects: 126
Study: 30288819

Group type: EXPERIMENTAL
Intervention: PacBio full-length cDNA sequencing integrated with RNA-seq reads
Number of subjects: 11733
Study: 29776672

Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 179

Group type: COMPARATOR
Intervention: High-density subthreshold micropulse laser (HSML)
Number of subjects: 179
Study: 26960195

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) with deep needling at BL33 and BL35
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham electroacupuncture (sham EA) with non-penetrating needling at sham acupoints
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham electroacupuncture (sham EA)
Number of subjects: 80
Study: 24562449

Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 160
Study: 22209386

Group type: EXPERIMENTAL
Intervention: Intranasal oxycodone 15 mg/70 kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intranasal oxycodone 30 mg/70 kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cold pressor testing (CPT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warm water control
Number of subjects: 20
Study: 19995475

Group type: EXPERIMENTAL
Intervention: Ketamine (0.54 mg/kg within 30 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17555820

Group type: EXPERIMENTAL
Intervention: 1CU IOL
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: AT‐45 IOL
Number of subjects: 79

Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 79
Study: 15805380

Group type: EXPERIMENTAL
Intervention: Lucinactant
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Colfosceril palmitate
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 1294
Study: 12510415

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Budesonide 400 mg twice a day
Number of subjects: 40
Study: 9856708

Group type: EXPERIMENTAL
Intervention: Systemic lidocaine (2 mg/kg bolus followed by 2 mg x kg(‐1) x h(‐1) infusion for 50 min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous regional anesthesia with lidocaine (40 ml, 0.05%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control with NaCl (0.9%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both treatments (systemic and regional lidocaine)
Number of subjects: 12
Study: 7697578

Group type: EXPERIMENTAL
Intervention: Brief physician interventions
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 11
Study: 2258248

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg oral dose
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 553663

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine inhalation
Number of subjects: 0
Study: 30880731

Group type: EXPERIMENTAL
Intervention: No scalpel vasectomy (NSV) awareness and acceptance
Number of subjects: 48
Study: 28739542

Group type: EXPERIMENTAL
Intervention: Math intervention
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Spelling intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Active learning (general)
Number of subjects: 28
Study: 25044531

Group type: EXPERIMENTAL
Intervention: SRP+AZM (500 mg oral delivery × 3 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: SRP+Placebo (OD × 3 days)
Number of subjects: 70
Study: 24366433

Group type: EXPERIMENTAL
Intervention: Hypotonic 0.18% sodium hyaluronate artificial tears
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sterile 0.9% sodium chloride solution (control)
Number of subjects: 50
Study: 23083066

Group type: EXPERIMENTAL
Intervention: CHMP 3×2 tablets per day
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: CHMP 2×2 tablets per day
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo (3×2 tablets per day)
Number of subjects: 351
Study: 19129308

Group type: EXPERIMENTAL
Intervention: Tai Chi group (n = 74)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (n = 62)
Number of subjects: 136
Study: 17558914

Group type: EXPERIMENTAL
Intervention: Magnetic endoscope imaging (MEI) during colonoscopy
Number of subjects: 419

Group type: COMPARATOR
Intervention: Standard colonoscopy without MEI
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Magnetic endoscope imaging (MEI) during colonoscopy by experienced colonoscopists
Number of subjects: 419

Group type: COMPARATOR
Intervention: Standard colonoscopy without MEI by experienced colonoscopists
Number of subjects: 419
Study: 14767083

Group type: EXPERIMENTAL
Intervention: MDI with spacer (400 micrograms salbutamol)
Number of subjects: 153

Group type: COMPARATOR
Intervention: DPI (rotahaler, 400 micrograms salbutamol)
Number of subjects: 153
Study: 11734733

Group type: EXPERIMENTAL
Intervention: Inactivated trivalent influenza vaccine
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Cold-adapted vaccine
Number of subjects: 791

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 791
Study: 9399001

Group type: EXPERIMENTAL
Intervention: Migraine sufferers
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Migraine sufferers with stronger odour perception during attacks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 41
Study: 7522282

Group type: EXPERIMENTAL
Intervention: Amlodipine (5‐10 mg, once daily)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Enalapril (10‐40 mg, once daily)
Number of subjects: 461
Study: 3439796

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 29069415

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccines (PCVs)
Number of subjects: 5224
Study: 26565716

Group type: EXPERIMENTAL
Intervention: Dapivirine (0.05%) gel
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dapivirine (1.25 mg) film
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo film
Number of subjects: 61
Study: 25948671

Group type: EXPERIMENTAL
Intervention: Highest quartile of SFA intake (>31.28 g/d)
Number of subjects: 1469

Group type: COMPARATOR
Intervention: Lowest quartile of SFA intake (<17.39 g/d)
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Baseline SFA intake
Number of subjects: 1469
Study: 23994919

Group type: EXPERIMENTAL
Intervention: Reosorbilact (200-400 ml intravenously for 20 days)
Number of subjects: 0
Study: 20338811

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (CY)
Number of subjects: 52
Study: 18218110

Group type: EXPERIMENTAL
Intervention: PRAFAB questionnaire (5-item)
Number of subjects: 279
Study: 12804135

Group type: EXPERIMENTAL
Intervention: Plasmid DNA encoding gp100 administered intradermally (n = 10)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Plasmid DNA encoding gp100 administered intramuscularly (n = 12)
Number of subjects: 22
Study: 9799058

Group type: EXPERIMENTAL
Intervention: Sum of parent compound and metabolite
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Parent compound
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Each metabolite
Number of subjects: 4
Study: 7617607

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2520143

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 405412

Group type: EXPERIMENTAL
Intervention: Chewable isosorbide dinitrate (I)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (N)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study: 31286260

Group type: EXPERIMENTAL
Intervention: Bovine-derived xenograft with 10% collagen and collagen membrane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bovine-derived xenograft particles and collagen membrane
Number of subjects: 40

Group type: COMPARATOR
Intervention: No grafting (spontaneous healing)
Number of subjects: 40
Study: 30345658

Group type: EXPERIMENTAL
Intervention: Daily text messages consisting of multiple-choice questions with links to online material
Number of subjects: 162

Group type: COMPARATOR
Intervention: No text messages (control group)
Number of subjects: 162
Study: 27815068

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir plus raltegravir
Number of subjects: 211

Group type: COMPARATOR
Intervention: Ritonavir-boosted lopinavir plus two or three N(t)RTIs
Number of subjects: 211
Study: 25902844

Group type: EXPERIMENTAL
Intervention: RUTF with elevated short chain n‐3 PUFA plus fish oil capsules
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RUTF with elevated short chain n‐3 PUFA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard RUTF
Number of subjects: 60
Study: 24209829

Group type: EXPERIMENTAL
Intervention: Immediate ART for 40 weeks (ART-40W)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Immediate ART for 96 weeks (ART-96W)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Deferred ART (ART-Def)
Number of subjects: 377
Study: 21227600

Group type: EXPERIMENTAL
Intervention: Δ⁹‐THC (30 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nabilone (1 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nabilone (3 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nabilone (1 mg) + Δ⁹‐THC (5 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nabilone (3 mg) + Δ⁹‐THC (15 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nabilone (3 mg) + Δ⁹‐THC (30 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 19938054

Group type: EXPERIMENTAL
Intervention: L-arginine supplementation
Number of subjects: 927

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study: 17898377

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Narcotrend (NCT) monitoring
Number of subjects: 12
Study: 15149420

Group type: EXPERIMENTAL
Intervention: RA mapping
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: LA mapping
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bachmann's bundle block
Number of subjects: 35
Study: 11499328

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tretinoin 0.1% gel microsponge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tretinoin 0.025% gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adapalene 0.1% gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tazarotene 0.1% gel (once-daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel (alternate-day)
Number of subjects: 0
Study: 9630388

Group type: COMPARATOR
Intervention: Selenium-enriched yeast, sodium selenate, or selenium-enriched wheat (Trial I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Selenium-enriched yeast, sodium selenate, or sodium selenite (Trial II)
Number of subjects: 50
Study: 7836711

Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2856602

Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine cream 1%
Number of subjects: 138

Group type: COMPARATOR
Intervention: Ciclopirox 1%-hydrocortisone acetate 1% cream
Number of subjects: 138
Study: 31350213

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-frequency repetitive transcranial magnetic stimulation (10 Hz rTMS)
Number of subjects: 0
Study: 27889221

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment (ET)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Antibiotic prophylaxis
Number of subjects: 77